PharmGen Science, Inc. (KRX:004720)

South Korea · Delayed Price · Currency is KRW

3,245.00

+120.00 (3.84%)

Aug 24, 2026, 3:30 PM KST

PharmGen Science Financials Overview

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	171,658	171,287	166,779	150,931	109,866	96,614
Revenue Growth	-0.02%	2.70%	10.50%	37.38%	13.72%	1.55%
Gross Profit	108,356	107,874	97,749	81,073	60,730	53,529
Operating Income	9,658	10,626	9,127	7,412	-4,938	-1,905
Net Income	117.75	2,791	6,089	70,060	32,466	9,222
Earnings Per Share	6.50	152.25	323.65	3369.29	1814.33	623.34
EPS Growth	-98.08%	-52.96%	-90.39%	85.70%	191.07%	2297.46%

Revenue by Geography

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
South Korea	170,979	170,609	165,885	150,065	109,543	96,061
Overseas	679.03	677.68	894.32	865.92	322.63	553.53
Total	171,658	171,287	166,779	150,931	109,866	96,614

Cash & Debt

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Investments	14,082	38,449	37,437	19,886	34,187	30,448
Total Debt	19,425	38,989	37,963	39,492	48,009	21,405
Net Cash (Debt)	-5,343	-540.17	-526.1	-19,606	-13,822	9,043
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share	-250.84	-24.80	-25.30	-908.04	-743.19	602.01

Cash Flow & CapEx

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Operating Cash Flow	-1,287	2,384	5,439	-1,286	7,784	2,676
Capital Expenditures	-652.9	-918.7	-2,266	-9,922	-30,750	-4,339
Free Cash Flow	-1,940	1,466	3,173	-11,208	-22,966	-1,664
Free Cash Flow Growth	-	-53.81%	-	-	-	-

Margins

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Gross Margin	63.12%	62.98%	58.61%	53.72%	55.28%	55.41%
Operating Margin	5.63%	6.20%	5.47%	4.91%	-4.49%	-1.97%
Pretax Margin	-1.30%	0.59%	5.07%	59.60%	38.18%	11.60%
Profit Margin	0.07%	1.63%	3.65%	46.42%	29.55%	9.54%
FCF Margin	-1.13%	0.86%	1.90%	-7.43%	-20.90%	-1.72%

Valuation

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Aug '26 Aug 25, 2026	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
PE Ratio	623.16	26.58	18.29	1.51	4.91	17.98
P/FCF Ratio	-	50.61	35.09	-	-	-
PS Ratio	0.43	0.43	0.67	0.70	1.45	1.72